Non-Immunotherapy Interventions May Successfully Target Renal Cell Carcinoma

Video

A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.

In an interview with CancerNetwork® at the 2023 Kidney Cancer Research Summit (KCRS), Rana R. McKay, MD, highlighted how non-immunotherapy–based treatments may provide benefit in renal cell carcinoma (RCC) by targeting the tumor, tumor microenvironment, and angiogenesis.

Although there is excitement in the field with regard to these agents, McKay, a board-certified medical oncologist and associate professor in the Department of Medicine at University of California, San Diego Health, emphasized the importance of finding new targets and researching tumor biology further to optimize patient outcomes. Additionally, she stated that the formation of partnerships with industry colleagues may help provide access to treatment with new agents among those with RCC.

Transcript:

There are a lot of novel therapies that are being developed for [RCC]. Specifically, my presentation focused on the novel, non-immunotherapy-based strategies. There are a couple of ways that we can continue to target the tumor and tumor microenvironment within renal cell carcinoma. We can continue to target the angiogenic axis, [as well as] target the tumor through direct cell killing through various agents that induce cell death, whether it be chemotherapy, radioligand therapy, or leveraging the concept of synthetic lethality to induce tumor kill. And then there are other targets that are worthy of exploration and other mechanisms of action that fall into a “grab bag” of other potential therapeutic strategies.

There’s been a lot of excitement around the new agents that are on the horizon, but quite honestly, we need more targets. We need a better understanding of the tumor biology to be able to identify additional therapeutic strategies and need additional drugs to ultimately enter the clinic and lead to improved outcomes for patients.

There are a lot of drugs that are continuing to be tested in renal cell carcinoma. There are novel delivery mechanisms that are now being tested. There are new targets that are being explored. But we need more innovation in this space, quite honestly. Hopefully, through partnership with our industry colleagues and others, we can work together to help bring new drugs and new agents into the clinic.

Reference

McKay RR. Novel therapies. Presented at: 2023 Kidney Cancer Research Summit; July 13-14, 2023; Boston, MA.

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Related Content